Dr. Hoos on Why Melanoma is Amenable to Immunotherapy | OncLive

Dr. Hoos on Why Melanoma is Amenable to Immunotherapy

July 26, 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, describes that melanoma has often been viewed as a disease that is susceptible to immunotherapy simply because of the various antigens that present in the disease. Hoos goes on to explain that other indications will need to be examined more in depth and could result in another disease that is just as amendable to immunotherapy as melanoma.


x